title: Amlodipine for migraine prophylaxis.
abstract: Migraine is among the most common neurologic disorders encountered in clinical practice. In the general US population, the annual incidence has been calculated to be approximately 250 per 100,000 with a point prevalence of 10%. Females are affected more than males. A variety of prophylactic and abortive medications are being used for treatment and several are being studied in clinical trials. Calcium-channel blockers are frequently used prophylactic medications. We report two patients with migraine successfully treated with amlodipine (Norvasc, Pfizer, Inc), a slow calcium-channel blocker. To our knowledge, these are the first reported cases of amlodipine used in migraine prophylaxis.
authors.affiliation: Department of Neurology, Cleveland Clinic Florida, 3000 West Cypress Creek Road, Fort Lauderdale, FL 33309, USA.
authors.forename: B K
authors.initials: BK
authors.lastname: Dandapani
authors.forename: M R
authors.initials: MR
authors.lastname: Hanson
mesh_terms: D000328:Adult; D017311:Amlodipine / Q000494:pharmacology / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*
chemical_list: D002121:Calcium Channel Blockers; D017311:Amlodipine